Drospirenone/ethinyl estradiol 3 mg/20 μg (24/4 day regimen): Hormonal contraceptive choices - Use of a fourth-generation progestin

Patient Preference and Adherence

Volumn 3, Issue , 2009, Pages 259-264

  Bachmann, Gloria ^a   Kopacz, Sharon ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Acne vulgaris; Antiandrogenic activity; Antimineralocorticoid activity; Contraception; Drospirenone; Premenstrual dysphoric disorder

Indexed keywords

EID: 77957710668     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S3901     Document Type: Review

References (16)

1. Mosher WD, Martinex GM, Chandra A. et al. Use of contraception and use of family planning services in the United States: 1982-2002. Adv Data. 2004;350:1-36.
2. Fenton C, Wellington K, Moen MD, Robinson DM. Drospirenone/ ethinylestradiol 3 mg/20 mcg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris. Drugs. 2007;67(12):1748-1765.
3. Bachmann G, Sulak PJ. Sampson-Landers C. et al. Efficacy and safety of a low dose 24 day combined oral contraceptive containing 20 mcg ethinylestradiol and 3 mg drospirenone. Contraception. 2004;70(3):191-198.
4. Premenstrual dysphoric disorder. In: First MB, editor. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington (DC): American Psychiatric Press; 2000. p. 771-774.
5. Steiner M Born L. Diagnosis and treatment of premenstrual dysphoric disorder: An update. Int Clin Psychopharmacol. 2000;15 Suppl 3: S5-S17.
6. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005;106: 492-501.
7. Koltun W, Lucky A, Thiboutot D, et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris:a randomized, doubleblind, placebo-controlled trial. Contraception. 2008;77:249-256.
8. De Leo V, Morgante G, Piomboni P, et al. Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyper-androgenic women with polycystic ovary syndrome. Fertil Steril. 2007;88(1):113-117.
9. Pérez-Lopéz FR. Clinical experiences with drospirenone: from reproductive to post-menopausal years. Maturitas. 2008;60(2): 78-91.
10. Klipping C and Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 mcg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception. 2005;71:409-416.
11. Koltun W, Lucky AW, Thiboutot D, et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception. 2008;77(4): 249-256.
12. Droegemuller, W. Endometriosis and adenomyosis: etiology, pathology, diagnosis and management. In: Stenchever, Droegemuller, Herbst, Michell, Editors. Comprehensive Gynecology. 2001. p. 531-564.
13. Hernadi L, Marr J, Petralgia F. Efficacy of a new low-dose 24-day combined oral contraceptive containing drospirenone 3 mg and ethinyl estradiol 20 ag [oral presentation]. XVIII World Congress of Gynecology and Obstetrics (FIGO) 2006 Nov 5-10: Kuala Lumpur.
14. Pearlstein TB, Bachmann GA, Zacur HA, et al. Treatment of premenstrual dysphoric disorder with a new drospirenone containing oral contraceptive formulation. Contraception. 2005:72(6): 414-421.
15. Cibula D, Karck U, Weidenhammer HG, Kunz J, Alinicic S, Marr J. Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20 mcg and drospirenone 3 mg. Clinical Drug Investig. 2006;26(3):143-150.
16. White WB, Hanes V, Korner P. Drospirenone and 17-B estradiol reduces 24 h BP in postmenopausal women with hypertension. Obstet Gynecol. 2006;107:23S-24S.